Alberico Del Torto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/35547/publications.pdf

Version: 2024-02-01

135 papers	11,993 citations	36303 51 h-index	28297 105 g-index
138 all docs	138 docs citations	138 times ranked	7693 citing authors

#	Article	IF	Citations
1	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
2	CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. New England Journal of Medicine, 2021, 385, 493-502.	27.0	807
3	Noncontrast T1 Mapping for the Diagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2013, 6, 488-497.	5.3	517
4	Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation, 2015, 132, 1570-1579.	1.6	442
5	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	2.2	434
6	Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping. Circulation: Cardiovascular Imaging, 2013, 6, 392-398.	2.6	399
7	A new staging system for cardiac transthyretin amyloidosis. European Heart Journal, 2018, 39, 2799-2806.	2.2	396
8	Native T1 Mapping in Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 157-165.	5.3	339
9	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure, 2019, 12, e006075.	3.9	312
10	T1 mapping and survival in systemic light-chain amyloidosis. European Heart Journal, 2015, 36, 244-251.	2.2	310
11	Magnetic Resonance in TransthyretinÂCardiac Amyloidosis. Journal of the American College of Cardiology, 2017, 70, 466-477.	2.8	290
12	Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation, 2019, 140, 16-26.	1.6	288
13	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	2.1	230
14	Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	210
15	Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 87.	3.3	207
16	Remote Ischemic Conditioning Reduces Myocardial Infarct Size and Edema in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2015, 8, 178-188.	2.9	199
17	Native T1 and Extracellular Volume inÂTransthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 810-819.	5.3	172
18	Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 99.	3.3	154

#	Article	IF	Citations
19	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526.	7.1	153
20	Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. Radiology, 2015, 277, 388-397.	7.3	146
21	Myocardial Edema and Prognosis inÂAmyloidosis. Journal of the American College of Cardiology, 2018, 71, 2919-2931.	2.8	145
22	Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. European Heart Journal, 2017, 38, 1905-1908.	2.2	144
23	Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMRÂtoÂDetect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction. JACC: Cardiovascular Imaging, 2019, 12, 1958-1969.	5.3	140
24	Multiparametric Echocardiography Scores for the Diagnosis of CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 909-920.	5.3	136
25	Cardiac amyloidosis. Clinical Medicine, 2018, 18, s30-s35.	1.9	135
26	A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. European Heart Journal, 2015, 36, 1098-1105.	2.2	129
27	Automatic Measurement of the MyocardialÂInterstitium. JACC: Cardiovascular Imaging, 2016, 9, 54-63.	5.3	127
28	Noncontrast Magnetic Resonance for theÂDiagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 69-80.	5.3	125
29	Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. European Heart Journal Cardiovascular Imaging, 2017, 18, 1344-1350.	1.2	124
30	Treatment of cardiac transthyretin amyloidosis: an update. European Heart Journal, 2019, 40, 3699-3706.	2.2	121
31	Residual Myocardial Iron Following Intramyocardial Hemorrhage During the Convalescent Phase of Reperfused ST-Segmentâ€“Elevation Myocardial Infarction and Adverse Left Ventricular Remodeling. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	120
32	Cardiac Structural and Functional Consequences of Amyloid Deposition byÂCardiac Magnetic Resonance andÂEchocardiography and TheirÂPrognosticÂRoles. JACC: Cardiovascular Imaging, 2019, 12, 823-833.	5.3	113
33	Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. JACC: Cardiovascular Imaging, 2021, 14, 189-199.	5.3	113
34	Prospective Case-Control Study of Cardiovascular Abnormalities 6ÂMonthsÂFollowing Mild COVID-19 inÂHealthcare Workers. JACC: Cardiovascular Imaging, 2021, 14, 2155-2166.	5.3	111
35	Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. Journal of Cardiovascular Computed Tomography, 2015, 9, 585-592.	1.3	108
36	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. European Heart Journal, 2020, 41, 1439-1447.	2.2	108

#	Article	IF	Citations
37	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	1.7	107
38	Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. Lancet Haematology,the, 2015, 2, e241-e250.	4.6	105
39	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	2.1	97
40	Incremental Prognostic Value of Myocardial Fibrosis in Patients With Nonâ€"Ischemic Cardiomyopathy Without Congestive Heart Failure. Circulation: Heart Failure, 2014, 7, 448-456.	3.9	94
41	Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Science Translational Medicine, 2018, 10, .	12.4	94
42	Diagnostic imaging of cardiac amyloidosis. Nature Reviews Cardiology, 2020, 17, 413-426.	13.7	84
43	Myocardial native T1 and extracellular volume with healthy ageing and gender. European Heart Journal Cardiovascular Imaging, 2018, 19, 615-621.	1.2	78
44	Dynamic Stress Computed Tomography Perfusion With a Whole-Heart Coverage Scanner in Addition to Coronary Computed Tomography Angiography and Fractional Flow Reserve ComputedÂTomography Derived. JACC: Cardiovascular Imaging, 2019, 12, 2460-2471.	5.3	76
45	Myocardial Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 2345-2356.	5.3	74
46	T1 mapping and T2 mapping at 3T for quantifying the area-at-risk in reperfused STEMI patients. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 73.	3.3	70
47	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	1.7	70
48	Dark blood late enhancement imaging. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 77.	3.3	64
49	RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nature Reviews Cardiology, 2022, 19, 655-667.	13.7	64
50	Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy. Journal of Cardiovascular Medicine, 2015, 16, 681.	1.5	61
51	Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 162-166.	3.0	61
52	Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARSâ€'CoV-2 infection. EBioMedicine, 2021, 65, 103259.	6.1	61
53	Defining left ventricular remodeling following acute ST-segment elevation myocardial infarction using cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 26.	3.3	55
54	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	2.6	48

#	Article	IF	Citations
55	Automated Extracellular Volume Fraction Mapping Provides Insights Into the Pathophysiology of Left Ventricular Remodeling Postâ€“Reperfused STâ€Elevation Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	3.7	46
56	Quantification of both the area-at-risk and acute myocardial infarct size in ST-segment elevation myocardial infarction using T1-mapping. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 57.	3.3	41
57	Lvad pump speed increase is associated with increased peak exercise cardiac output and vo2, postponed anaerobic threshold and improved ventilatory efficiency. International Journal of Cardiology, 2017, 230, 28-32.	1.7	39
58	T1 Mapping for Characterization of Intracellular and Extracellular Myocardial Diseases in Heart Failure. Current Cardiovascular Imaging Reports, 2014, 7, 9287.	0.6	37
59	Determinants of Rejection Rate for Coronary CT Angiography Fractional Flow Reserve Analysis. Radiology, 2019, 292, 597-605.	7.3	37
60	Prospective comparison of novel dark blood late gadolinium enhancement with conventional bright blood imaging for the detection of scar. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 91.	3.3	36
61	T1 mapping and cardiac magnetic resonance feature tracking in mitral valve prolapse. European Radiology, 2021, 31, 1100-1109.	4.5	36
62	Critical Comparison of Documents FromÂScientific Societies on CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2022, 79, 1288-1303.	2.8	35
63	Automatic quantification of the myocardial extracellular volume by cardiac computed tomography: Synthetic ECV by CCT. Journal of Cardiovascular Computed Tomography, 2017, 11, 221-226.	1.3	34
64	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	2.1	34
65	Automated Inline Analysis of Myocardial Perfusion MRI with Deep Learning. Radiology: Artificial Intelligence, 2020, 2, e200009.	5.8	32
66	Insight into hypertrophied hearts: a cardiovascular magnetic resonance study of papillary muscle mass and T1 mapping. European Heart Journal Cardiovascular Imaging, 2017, 18, 1034-1040.	1.2	31
67	Therapies for cardiac light chain amyloidosis: An update. International Journal of Cardiology, 2018, 271, 152-160.	1.7	31
68	Visceral Adiposity Index (VAI) in Children and Adolescents with Obesity: No Association with Daily Energy Intake but Promising Tool to Identify Metabolic Syndrome (MetS). Nutrients, 2021, 13, 413.	4.1	31
69	Assessment of Multivessel Coronary Artery Disease Using Cardiovascular Magnetic Resonance Pixelwise Quantitative Perfusion Mapping. JACC: Cardiovascular Imaging, 2020, 13, 2546-2557.	5.3	30
70	Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. Human Mutation, 2019, 40, 90-96.	2.5	29
71	Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance. Scientific Reports, 2019, 9, 1388.	3.3	27
72	Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. European Heart Journal, 2022, 43, 2622-2632.	2.2	27

#	Article	IF	Citations
73	Diffusion Tensor Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2020, 13, e009901.	2.6	26
74	Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. European Journal of Heart Failure, 2022, 24, 1700-1712.	7.1	26
75	Diagnostic performance of T₁ and T₂ mapping to detect intramyocardial hemorrhage in reperfused STâ€segment elevation myocardial infarction (STEMI) patients. Journal of Magnetic Resonance Imaging, 2017, 46, 877-886.	3.4	24
76	Landmark Detection in Cardiac MRI by Using a Convolutional Neural Network. Radiology: Artificial Intelligence, 2021, 3, e200197.	5.8	24
77	Ultrafast Magnetic Resonance Imaging for Iron Quantification in Thalassemia Participants in the Developing World. Circulation, 2016, 134, 432-434.	1.6	23
78	Relative Left Ventricular Apical Sparing of Longitudinal Strain in Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 1174-1176.	5.3	23
79	Diagnostic accuracy of simultaneous evaluation of coronary arteries and myocardial perfusion with single stress cardiac computed tomography acquisition compared to invasive coronary angiography plus invasive fractional flow reserve. International Journal of Cardiology, 2018, 273, 263-268.	1.7	22
80	Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Failure, 2020, 7, 3942-3949.	3.1	22
81	Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities. Journal of the American Heart Association, 2019, 8, e012097.	3.7	21
82	Sequential Strategy Including FFRCT Plus Stress-CTP Impacts on Management of Patients with Stable Chest Pain: The Stress-CTP RIPCORD Study. Journal of Clinical Medicine, 2020, 9, 2147.	2.4	21
83	Contribution of central and peripheral factors at peak exercise in heart failure patients with progressive severity of exercise limitation. International Journal of Cardiology, 2017, 248, 252-256.	1.7	20
84	Automated detection of left ventricle in arterial input function images for inline perfusion mapping using deep learning: A study of 15,000 patients. Magnetic Resonance in Medicine, 2020, 84, 2788-2800.	3.0	19
85	Cardiac Magnetic Resonanceâ€“Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid. Circulation: Cardiovascular Imaging, 2021, 14, CIRCIMAGING121012506.	2.6	19
86	Role of CMR Mapping Techniques in Cardiac Hypertrophic Phenotype. Diagnostics, 2020, 10, 770.	2.6	19
87	Impact of microvascular obstruction on semiautomated techniques for quantifying acute and chronic myocardial infarction by cardiovascular magnetic resonance. Open Heart, 2016, 3, e000535.	2.3	18
88	Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis. Nephrology Dialysis Transplantation, 2016, 33, gfw375.	0.7	18
89	Prognostic Value of Pulmonary Transit Time and Pulmonary Blood Volume Estimation Using Myocardial PerfusionÂCMR. JACC: Cardiovascular Imaging, 2021, 14, 2107-2119.	5.3	18
90	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€”Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	2.6	16

#	Article	IF	Citations
91	Cardiac Amyloidosis: A Review of Current Imaging Techniques. Frontiers in Cardiovascular Medicine, 2021, 8, 751293.	2.4	16
92	Quantitative cardiovascular magnetic resonance myocardial perfusion mapping to assess hyperaemic response to adenosine stress. European Heart Journal Cardiovascular Imaging, 2021, 22, 273-281.	1.2	15
93	Demographic, multi-morbidity and genetic impact on myocardial involvement and its recovery from COVID-19: protocol design of COVID-HEARTâ€"a UK, multicentre, observational study. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 77.	3.3	14
94	Acute Increase of CardiacÂOutput Reduces Central Sleep Apneas in Heart Failure Patients. Journal of the American College of Cardiology, 2015, 66, 2571-2572.	2.8	13
95	A workflow for patient-specific fluidâ€"structure interaction analysis of the mitral valve: A proof of concept on a mitral regurgitation case. Medical Engineering and Physics, 2019, 74, 153-161.	1.7	13
96	Society for Cardiovascular Magnetic Resonance (SCMR) guidance for re-activation of cardiovascular magnetic resonance practice after peak phase of the COVID-19 pandemic. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 58.	3.3	13
97	Effect of remote ischaemic conditioning on infarct size and remodelling in ST-segment elevation myocardial infarction patients: the CONDI-2/ERIC-PPCI CMR substudy. Basic Research in Cardiology, 2021, 116, 59.	5.9	13
98	Society for Cardiovascular Magnetic Resonance (SCMR) guidelines for reporting cardiovascular magnetic resonance examinations. Journal of Cardiovascular Magnetic Resonance, 2022, 24, 29.	3.3	13
99	Staging Cardiac Amyloidosis With CMR. JACC: Cardiovascular Imaging, 2016, 9, 1278-1279.	5.3	10
100	The value of screening biopsies in lightâ€chain (AL) and transthyretin (ATTR) amyloidosis. European Journal of Haematology, 2020, 105, 352-356.	2.2	10
101	Quantitative Myocardial Perfusion Predicts Outcomes in Patients With Prior SurgicalÂRevascularization. Journal of the American College of Cardiology, 2022, 79, 1141-1151.	2.8	10
102	A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid. BMC Medical Imaging, 2017, 17, 3.	2.7	9
103	Do Preâ€Hemodialysis Estimates of Extracellular Volume Excess Using Bioimpedance and Nâ€Terminal Brain Natriuretic Peptide Correlate With Cardiac Chamber Size Measured by Magnetic Resonance Imaging?. Therapeutic Apheresis and Dialysis, 2019, 23, 362-368.	0.9	9
104	Nutripedia: The Fight against the Fake News in Nutrition during Pregnancy and Early Life. Nutrients, 2021, 13, 2998.	4.1	9
105	Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Heart, 2022, 108, 474-478.	2.9	8
106	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2022, 28, e1-e4.	1.7	8
107	Advances in Multimodality Cardiovascular Imaging in the Diagnosis of Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2022, 9, 758975.	2.4	8
108	Extracellular volume with bolusâ€only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time. Journal of Magnetic Resonance Imaging, 2018, 47, 1677-1684.	3.4	7

#	Article	IF	Citations
109	Asymptomatic health-care worker screening during the COVID-19 pandemic â€“ Authors' reply. Lancet, The, 2020, 396, 1394-1395.	13.7	7
110	Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis. Cardiology Clinics, 2021, 39, 389-402.	2.2	7
111	Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study. European Heart Journal Cardiovascular Imaging, 2023, 24, 463-471.	1.2	7
112	Full left ventricular coverage is essential for the accurate quantification of the area-at-risk by T1 and T2 mapping. Scientific Reports, 2017, 7, 4871.	3.3	6
113	Hemodialysis patients with less extracellular water overload and smaller cardiac atrial chamber sizes are at greater risk of a fall in blood pressure during dialysis. Therapeutic Apheresis and Dialysis, 2021, 25, 16-23.	0.9	6
114	Cardiac output changes during exercise in heart failure patients: focus on midâ€exercise. ESC Heart Failure, 2021, 8, 55-62.	3.1	6
115	High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study. Sleep Medicine, 2017, 32, 191-197.	1.6	5
116	Cardiovascular Magnetic Resonance Parametric Mapping Techniques: Clinical Applications and Limitations. Current Cardiology Reports, 2021, 23, 185.	2.9	5
117	SCMR level II/independent practitioner training guidelines for cardiovascular magnetic resonance: integration of a virtual training environment. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 139.	3.3	5
118	Response to Letters Regarding Article, â€œPrognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosisâ€• Circulation, 2016, 133, e450-1.	1.6	4
119	Prognosis in Cardiac Amyloidosis by LGE. JACC: Cardiovascular Imaging, 2016, 9, 687-689.	5.3	4
120	Is Macronutrients Intake a Challenge for Cardiometabolic Risk in Obese Adolescents?. Nutrients, 2020, 12, 1785.	4.1	4
121	Reduced exercise capacity in patients with systemic sclerosis is associated with lower peak tissue oxygen extraction: a cardiovascular magnetic resonance-augmented cardiopulmonary exercise study. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 118.	3.3	4
122	A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 72-73.	3.0	3
123	Cardiac computed tomography for the detection of cardiac amyloidosis. Journal of Cardiovascular Computed Tomography, 2017, 11, 155-156.	1.3	3
124	The UK National Amyloidosis Centre. European Heart Journal, 2019, 40, 1661-1664.	2.2	3
125	A case report of eosinophilic granulomatosis and polyangiitis myocarditis presenting as ST elevation myocardial infarction and showing positive response to immunotherapy. European Heart Journal - Case Reports, 2019, 3, 1-6.	0.6	3
126	Anomalous origin of the left circumflex artery from the right coronary sinus with retro-aortic course: A potential malign variant. Journal of Cardiovascular Computed Tomography, 2020, 14, e54-e55.	1.3	3

#	Article	IF	Citations
127	Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin lightâ€chain (AL) amyloidosis. British Journal of Haematology, 2021, 194, 1016-1023.	2.5	3
128	Atrial Involvement in Cardiac Amyloidosis. JACC: CardioOncology, 2020, 2, 732-734.	4.0	3
129	The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis. Blood, 2020, 136, 16-17.	1.4	2
130	Interrogation of the infarcted and salvaged myocardium using multi-parametric mapping cardiovascular magnetic resonance in reperfused ST-segment elevation myocardial infarction patients. Scientific Reports, 2019, 9, 9056.	3.3	1
131	Detailed Understating of CardiacÂAmyloidosis by CMR. JACC: Cardiovascular Imaging, 2020, 13, 1311-1313.	5.3	1
132	The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis. Blood, 2020, 136, 40-40.	1.4	1
133	Intracardiac melanoma metastases on ¹⁸F-FDG PET-CTâ€"a case report and review of literature with imaging features. BJR|case Reports, 2019, 5, 20180118.	0.2	0
134	Pearls from the First Gulf Cardiac Amyloidosis Summit 2021. Emirates Medical Journal, 2022, 3, 1-11.	0.3	0
135	Comparison of 99mTc-DPD Scintigraphy, CMR Imaging, and Echocardiography in Patients With V30M-Associated Hereditary Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2022, , .	5.3	0